Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 224-924-0 | CAS number: 4553-89-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
The No Observed Adverse Effect Level (NOAEL) for Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) in male/ female Wistar rats was found to be 500 mg/Kg/day
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- data from handbook or collection of data
- Justification for type of information:
- Data is from a peer reviewed publication
- Qualifier:
- according to guideline
- Guideline:
- other: as mentioned below
- Principles of method if other than guideline:
- The effect of Chocolate Brown HT on Wistar derived rats was studied with respect to mortality, body-weight gain, food or water consumption, haematology, renal function, serum constituents, organ weight or histopathology and carcinogenicity over a period of 2 yrs.
- GLP compliance:
- not specified
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: No data available
- Age at study initiation: No data available
- Weight at study initiation:
Males: 54-80 g
Females: 53-82 g
- Fasting period before study: No data available
- Housing: 4/cage
- Diet (e.g. ad libitum): ground Spratts Laboratory Diet No.1 ad libitum
- Water (e.g. ad libitum): Water ad libitum
- Acclimation period: No data available
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20± 1 OC
- Humidity (%): 50-60%
- Air changes (per hr): No data available
- Photoperiod (hrs dark / hrs light): No data available
IN-LIFE DATES: From: To: No data available - Route of administration:
- oral: feed
- Vehicle:
- other: Spratts Laboratory Diet No. 1
- Details on exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): No data available
- Mixing appropriate amounts with (Type of food): ground Spratts Laboratory Diet No.1 ad libitum
- Storage temperature of food: No data available
VEHICLE
- Justification for use and choice of vehicle (if other than water): No data available
- Concentration in vehicle: 0, 25, 100 and 500 mg/Kg/day in the diet
- Amount of vehicle (if gavage): No data available
- Lot/batch no. (if required): No data available
- Purity: No data available - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- daily
- Post exposure period:
- no details available
- Remarks:
- Doses / Concentrations:
0, 25, 100 and 500 mg/Kg/day
Basis:
nominal in diet - No. of animals per sex per dose:
- 48 /sex/dose
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- No data available
- Positive control:
- No data available
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data
- Time schedule:
- Cage side observations checked in table [No.?] were included.
DETAILED CLINICAL OBSERVATIONS: No data
- Time schedule:
BODY WEIGHT: Yes
- Time schedule for examinations: First day of feeding and at week 1,4, 7 and 11 of treatment
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: Yes
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: measured over the 48-h period commencing at the same time as the food intake
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined:
HAEMATOLOGY: Yes
- Time schedule for collection of blood: At week 14, 27, 55 and 80
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: 10 male and 10 female rats
- Parameters checked in table [No.?] were examined: Haemoglobin content, packed cell volume and counts of erythrocytes and total leucocytes. Reticulocyte and differential white cell counts were carried out in blood samples from control rats and those given 500mg/Kg/bw Chocolate Brown HT in the diet for 14 and 27 weeks only
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: After week 104
- Animals fasted: No data
- How many animals:
- Parameters checked in table [No.?] were examined: Serum was analysed for its content of urea, glucose, total protein and albumin and for the activities of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase and lactic dehydrogenase
URINALYSIS: Yes
- Time schedule for collection of urine: At weeks 14, 27, 56 and 102
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters checked in table [No.?] were examined.
NEUROBEHAVIOURAL EXAMINATION: No
- Time schedule for examinations:
- Dose groups that were examined: No data
- Battery of functions tested: sensory activity / grip strength / motor activity / other: No data
OTHER: - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes; the brain,
heart, liver, spleen, kidneys, stomach, small intestine, caecum, adrenals,
gonads, pituitary and thyroid were weighed.
HISTOPATHOLOGY: Yes; Samples of the brain, heart, liver, spleen, kidneys, stomach, small intestine, caecum, adrenals, gonads, pituitary and thyroid together with samples of all major tissues and organs and of any other tissue appearing abnormal at autopsy were preserved in 10% buffered formalin until prepared for histological examination. - Statistics:
- Statistical calculations are based on a level of significance of at least P = 0.05.
- Clinical signs:
- no effects observed
- Description (incidence and severity):
- Cumulative mortality observed was similar in the treated and control animals throughout the 2-year period
- Mortality:
- no mortality observed
- Description (incidence):
- Cumulative mortality observed was similar in the treated and control animals throughout the 2-year period
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- No statistically significant differences between treated and control animals observed.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- No statistically significant differences between treated and control animals observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences between treated and control animals in the terminal haematological studies. Any hematological changes detected were not considered to be treatment related
- Clinical biochemistry findings:
- no effects observed
- Description (incidence and severity):
- No significant differences between treated and control animals observed
- Urinalysis findings:
- no effects observed
- Description (incidence and severity):
- No significant differences between treated and control animals observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- The only statistically significant differences between treated and control rats were slightly higher relative spleen and kidney weights in males given dose at 500 mg/Kg day and a slightly higher relative spleen weight in females given 25mg/Kg day
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- High incidence of adenosis and fibroadenosis in the female rats, but the incidences in the treated and control animals showed no statistical differences.
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY: Cumulative mortality was similar in the treated and control animals throughout the 2-year period except for one statistically significant value at week 72 (7 deaths compared with none in the controls) in males given 500mg/Kg/day
BODY WEIGHT AND WEIGHT GAIN: No data available
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): No statistically significant differences between treated and control animals observed.
The approximate total intakes of the colouring consumed per rat up to week 66 for the high treatment levels was 109.8 g for males and 83.9 g for female rats. The corresponding values up to week 102 were 160.8 g/rat by the males and 128.2 g/rat for the females.
FOOD EFFICIENCY: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No statistically significant differences between treated and control animals observed
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: There were several isolated statistically significant differences between treated and control rats in the results of the interim haematological examinations. These consisted of a reduced haemoglobin concentration in males given 500 mg/Kg/day for 27 weeks and a reduced red cell count in females fed diets containing 500 mg/Kg/day for 27 weeks. In addition, the white cell counts were higher than the control value in females given 500 mg/Kg/day of the colouring for 14 weeks. There were no statistically significant differences between treated and control animals in the terminal haematological studies.
Any hematological changes detected were not considered to be treatment related.
CLINICAL CHEMISTRY: No significant differences between treated and control animals observed
URINALYSIS: No significant differences between treated and control animals observed
NEUROBEHAVIOUR: No data
ORGAN WEIGHTS:
The only statistically significant differences between treated and control rats in relative organ weights were slightly higher relative spleen and kidney weights in males given diet containing 500 mg/Kg day Chocolate Brown HT
GROSS PATHOLOGY: No indication of pigmentation or storage phenomena was observed in any tissues.
HISTOPATHOLOGY: NON-NEOPLASTIC: High incidence of adenosis and fibroadenosis in the female rats, but the incidences in the treated and control animals showed no statistical differences.
The incidence of tumours was low in all groups, the most common tumours being mammary adenomas and fibroadenomas in the female rats, interstitial cell tumours of the testis, and subcutaneous fibromas in both sexes. The incidence of these findings in the treated and control animals did not differ statistically. Very few of the tumours were malignant.
HISTOPATHOLOGY: NEOPLASTIC (if applicable)
HISTORICAL CONTROL DATA (if applicable): No data - Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 500 mg/kg bw/day
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Tumorogenic but not treatment related Clinical signs, body weight changes, hematological studies, urinalysis, clinical chemistry, gross and histopathology and carcinogenicity
- Conclusions:
- The No Observed Adverse Effect Level (NOAEL) for Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) in male/ female Wistar rats was found to be 500 mg/Kg/day
- Executive summary:
The effect of Chocolate Brown HT ( Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) on male and female Wistar rats was studied. The test material was given in the diet for 2 years. These treatments had no adverse effect on mortality, body-weight gain, food or water consumption, haematology, renal function, serum constituents, organ weight or histopathology. The scattered changes detected in the haematological studies at weeks 14, 27 and 55 were not related to treatment and none of these differences were evident at weeks 80 or 104. No effects attributable to treatment were detected by urine examination, renal concentration tests or serum analysis. In rats showing some reduction in testis weight, no lesions differing in type or incidence from those in control rats were found on histological examination. The incidence of testicular tumours was lower in this group than in the control rats. Thus this decreased testicular weight cannot have been related to treatment. The incidence of tumours in this study was low and was clearly unrelated to treatment, being similar in both test and control groups.
The No Observed Adverse Effect Level (NOAEL)for Chocolate Brown HT in male/ female Wistar rats was found to be 500 mg/Kg/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 500 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Data is of K2 level from a peer reviewed publication
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the available information from reliable sources, the substance is likely to be non-carcinogenic.
Additional information
Based on the available data for carcinogenicity of the target substance disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate the following results are summarized:
In key study, the effect of Chocolate Brown HT ( Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate) on male and female Wistar rats was studied. The test material was given in the diet for 2 years. These treatments had no adverse effect on mortality, body-weight gain, food or water consumption, haematology, renal function, serum constituents, organ weight or histopathology. The scattered changes detected in the haematological studies at weeks 14, 27 and 55 were not related to treatment and none of these differences were evident at weeks 80 or 104. No effects attributable to treatment were detected by urine examination, renal concentration tests or serum analysis. In rats showing some reduction in testis weight, no lesions differing in type or incidence from those in control rats were found on histological examination. The incidence of testicular tumours was lower in this group than in the control rats. Thus this decreased testicular weight cannot have been related to treatment. The incidence of tumours in this study was low and was clearly unrelated to treatment, being similar in both test and control groups. The No Observed Adverse Effect Level (NOAEL) for Chocolate Brown HT in male/ female Wistar rats was found to be 500 mg/Kg/day.
While in supporting study, Groups of 48 male and 48 female mice were given diets containing 0, 14.3, 143 and approx. 715 mg/kg/day Chocolate Brown HT (Disodium 4,4'-[[2,4-dihydroxy-5-(hydroxymethyl)-1,3-phenylene]bis(azo)]bisnaphthalene-1-sulphonate)for 80 weeks. There was a slightly reduced body weight gain and a lower heart weight in males given the highest dietary level. At the same level at week 77 the packed cell volume and total leucocyte count values in females were lower than those of the controls. However, the relationship of these findings to the treatment was questionable, as was the increased incidence of leucocytic infiltration of the liver in the female mice at the approx. 715 mg/Kg/day of treatment. A brown coloration of internal organs seen at the highest treatment level was due probably to the Chocolate Brown HT. The distribution of tumours was similar in all groups, lymphosarcomata were more frequently found in the treated animals, though there was no indication of any dose frequency relationship and it was concluded that there was no evidence of a carcinogenic effect with doses up to approx. 715 mg/kg/day was observed. The carcinogenicity No Observed Effect Level (NOEL) for the given test material is found to be approx. 715 mg/kg/day.
Based on the studies summarized above it can be observed that the substance did not showed any evidence of carcinogenic effects. Thus based on the above values it can be concluded that target substance (CAS NO 4553-89-3) is considered to be non carcinogenic in nature.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.